Indianapolis, Indiana -- Biotech company Algaeon has received $262,000 in new equity venture investment, according to an SEC regulatory filing.
Algaeon provides products that it derives from algae "to companies in the human nutraceutical and fish feed industries."
The company's products promise to improve human and animal immune system function.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
One investor made the investment.
Algaeon is still seeking $4.2 million in additional equity investment, according to the filing.
Minimum investment size per investor was listed as $75,000.